Jonas Heymann (@HeymannJonas) profile picture

Associate Professor of Clinical Pathology and Laboratory Medicine, Papanicolaou Cytology Laboratory, New York-Presbyterian Hospital-Weill Cornell Medicine

Joined August 2018
Past president of @cytopathology, @CancerCytopath Editorial Board member, and noted sage @mtsiddi will be there, too! @WCMCPathology #ASCyto26
#ASCyto26 | At 8am this morning, @HeymannJonas leads the Digital Slide Workshop on Pancreatic Aspiration Cytology: An Algorithmic Approach to Morphology, Reporting, and Molecular and Other Ancillary Testing 🔬 Don't miss it! #CytoPath
2
6
348
TFW you're on your way to #JFK for your flight to #SEA and #ASCyto26, casually listening to world experts discuss #thyroid #FNA #cytology. It's a pretty specific feeling. @CancerCytopath @bfaquin @ZMaleki_cyto @auger_manon pca.st/episode/79e0ddd5-a1ed…
5
7
281
New commentary from @eva_wojcik | Beyond morphology: Toward integrated risk assessment in urinary cytology acsjournals.onlinelibrary.wi… #CytoPath @loyolapathology
8
9
528
New this week | Diagnostic utility of cytologic sampling for main pancreatic duct abnormalities: A decade of institutional experience acsjournals.onlinelibrary.wi… #CytoPath @MLisaZhang
13
26
1,104
Heading to #AMP2026 and wondering what to do before the meeting starts? Join us at Special Programs Day for @cytopathology session, Nov 10 at 5 pm Included with your meeting registration but you have to sign up Maximizing #CytoPath for #MolPath 🧬 #supernatants #NGS @AMPath
1
10
24
940
#OpenAccess! Ultrarapid BRAF mutation detection on supernatant cell-free DNA obtained by FNA: An accurate and expedient method for BRAF assessment in aggressive thyroid carcinomas acsjournals.onlinelibrary.wi… #CytoPath @carliesigel
10
2
16
2,461
New and #OpenAccess! | Preanalytical variables affect predictive immunohistochemical biomarker testing in non–small cell lung carcinoma cytology specimens acsjournals.onlinelibrary.wi… #CytoPath @Sinchita_Roy @Saroja_DeviG
11
1
21
1,622
Jonas Heymann retweeted
Holy Grail or holy sh..t? Very intriguing results from the PATHFINDER-2 trial with Galleri MCED test - trial does not reach its endpoint (of reducing n of 12 index st 3/4 cancers by 3 yrs) but still… notable separation of stage 4 cancer detection curves at 3 yrs+ so maybe endpoint was overoptimistic/too early? Despite very high specificity, low prevalence yields more false neg than true pos results so similar to scanxiety…. With MCED tests we will run risk of creating a new emotion: MSAD…
In a trial of a blood-based multicancer early-detection test added to usual care, the incidence of stage III or IV cancer after three rounds of screening did not differ significantly from that with usual care alone. Full NHS-Galleri trial results: nej.md/4xRZN5L Editorial: A Step in the Search for the Elusive Holy Grail of Early Detection of Cancer nej.md/4cK3UIy
7
6
27
7,223
It's always difficult to differentiate the stars that are rising from those that are risen. Either way, this is a young man you should get to know! acsjournals.onlinelibrary.wi… @CancerCytopath @cytopathology @Pathologists
4
176
File this under reviews that will change your perspective. And for the #molpath community, please help me wrap my head around how we can detect the alterations depicted in Fig. 4C. @TheNixonLab rdcu.be/fy0He
2
182
Jonas Heymann retweeted
Early detection of cancer! Read more about it in Cancer Cytopathology! @MGBpathology @CancerCytopath @ACSNews doi.org/10.1002/cncy.70128
7
14
889
Replying to @CancerCytopath
RET mutations are the most common molecular alterations in MTC in both somatic and familial MTC, very important in treatment with target RET inhibitors, second common is RAS mutations #cytochat @CancerCytopath @bfaquin @MarcPusztaszeri @IvanaKholova @MichiyaNishino
1
1
6
101
In fair Verona . . . er, Naples (and Houston!), where we lay our scene. #Shakespeare #DNA
✉️ New Letter to the Editor | Supernatant: What’s in a name? Without a gold standard for supernatant preparations, molecular results hardly can be compared across studies, affecting their reproducibility. acsjournals.onlinelibrary.wi… #CytoPath @Sinchita_Roy @pathologyfinder
3
448
#CytoChat is back! ⚡ Join us June 18 at 11am ET as we discuss Practice Essentials of diagnostic challenges in medullary thyroid carcinoma by @MarcPusztaszeri and @ZMaleki_cyto. acsjournals.onlinelibrary.wi… @bfaquin @MichiyaNishino @HeymannJonas @IvanaKholova #CytoPath
2
9
1
25
1,817
The rates of HPV negative lesions are . . . concerning. Thank you to @AmericanCancer for continuing this important conversation around #HPV testing.
New & #OpenAccess 📄🔓 Pap testing and high-risk HPV testing for women aged 65 years and older with surgical pathology follow-up acsjournals.onlinelibrary.wi… @SamKhader @UPMCPathology #CytoPath #GynPath #SurgPath
1
3
144